Cantor Fitzgerald Reiterates Overweight on Intellia Therapeutics, Maintains $65 Price Target
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Rick Bienkowski has reiterated an Overweight rating on Intellia Therapeutics (NASDAQ:NTLA) and maintained a $65 price target.
September 13, 2023 | 12:26 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Cantor Fitzgerald has reiterated an Overweight rating on Intellia Therapeutics and maintained a $65 price target.
The reiteration of an Overweight rating by Cantor Fitzgerald indicates a positive outlook for Intellia Therapeutics. The maintained price target of $65 suggests that the analyst believes the stock is still undervalued, which could lead to upward pressure on the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100